RDM1 promotes prostate cancer cell progression through CDK4

doi:10.3877/cma.j.issn.1674-3253.2024.06.014

Abstract

Abstract:

Objective

To investigate the expression of RDM1 in prostate cancer and its role in prostate cancer progress.

Methods

The TCGA database，prostate cancer tissues and cell lines were used to analyze the expression of RDM1 in prostate cancer. Survival analysis and COX regression confirmed the correlation between RDM1 and the prognosis of prostate cancer patients. Enrichment analysis，CCK8，cell flow cytometry，plate cloning experiment，EdU staining and Western Blotting experiment were used to analyze the role and mechanism of RDM1 in prostate cancer cells.

Results

The expression of RDM1 was significantly increased in prostate cancer and was positively correlated with poor prognosis of patients.In addition，RDM1 is an independent risk factor affecting the overall survival time of prostate cancer patients. Functionally，RDM1 enhanced the ability of proliferation in prostate cancer cells. Mechanistically，RDM1 promotes the G₀/G₁ to the S phase by upregulating the expression of CDK4，ultimately promoting the proliferation of prostate cancer cells.

Conclusion

RDM1 is highly expressed in prostate cancer and can promote the proliferation of prostate cancer cells. It is expected to become a novel target for prostate cancer treatment.

Key words: Prostate cancer, RDM1, CDK4, Cell Cycle, Proliferation, Big data

Wei'an Zhu, Huahui Lin, Jianjie Wu, Jiongduan Huang, Tingting Wu, Wenjie Lai. RDM1 promotes prostate cancer cell progression through CDK4[J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(06): 618-625.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2024.06.014

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2024/V18/I06/618

Figures/Tables 6

References 27

［1］	Giri VN，Morgan TM，Morris DS，et al. Genetic testing in prostate cancer management: considerations informing primary care［J］. CA Cancer J Clin，2022，72（4）: 360-371.
［2］	李宛如，陈光锋，杨婷，等. ⁶⁸Ga标记的磁性铁氧体纳米颗粒PET/MRI双模态显像探针的制备及研究［J］. 中山大学学报（医学科学版），2022，43（3）: 430-436.Li WR，Chen GF，Yang T，et al. Investigation of ⁶⁸Ga-labeled magnetic ferrite nanoparticles PET/MRI dual-modal imaging probe［J］. J Sun Yat Sen Univ Med Sci，2022，43（3）: 430-436.
［3］	Tang F，Xu D，Wang S，et al. Chromatin profiles classify castrationresistant prostate cancers suggesting therapeutic targets［J］. Science，2022，376（6596）: e1505.
［4］	Chou C，Zhang X，Krishna C，et al. Programme of self-reactive innate-like T cell-mediated cancer immunity［J］. Nature，2022，605（7908）: 139-145.
［5］	Wongpalee SP，Liu S，Gallego-Bartolomé J，et al. CryoEM structures of Arabidopsis DDR complexes involved in RNA-directed DNA methylation［J］. Nat Commun，2019，10（1）: 3916.
［6］	Tong L，Cao W，Sheng J，et al. RDM1 plays an oncogenic role in human ovarian carcinoma cells［J］. Artif Cells Nanomed Biotechnol，2020，48（1）: 885-892.
［7］	Chen Y，Sun Z，Zhong T. RDM1 promotes critical processes in breast cancer tumorigenesis［J］. J Cell Mol Med，2019，23（8）: 5432-5439.
［8］	Chen SL，Liu LL，Wang CH，et al. Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways［J］. Mol Oncol，2020，14（2）: 373-386.
［9］	Lai W，Zhu W，Xiao C，et al. HJURP promotes proliferation in prostate cancer cells through increasing CDKN1A degradation via the GSK3β/JNK signaling pathway［J］. Cell Death Dis，2021，12（6）:583.
［10］	Zhong S，Xu Y，Yu C，et al. Anaphase-promoting complex/cyclosome regulates RdDM activity by degrading DMS3 in Arabidopsis［J］. Proc Natl Acad Sci USA，2019，116（9）: 3899-3908.
［11］	Xing Y，Xie Z，Sun W，et al. The RNA directed DNA Methylation（RdDM） pathway regulates anthocyanin biosynthesis in crabapple（Malus cv. spp.） Leaves by methylating the mccop1 promoter［J］.Plants （Basel），2021，10（11）.
［12］	Cleary JM，Aguirre AJ，Shapiro GI，et al. Biomarker-guided development of DNA repair inhibitors［J］. Mol Cell，2020，78（6）:1070-1085.
［13］	Groelly FJ，Fawkes M，Dagg RA，et al. Targeting DNA damage response pathways in cancer［J］. Nat Rev Cancer，2023，23（2）: 78-94.
［14］	Helleday T，Rudd SG. Targeting the DNA damage response and repair in cancer through nucleotide metabolism［J］. Mol Oncol，2022，16（21）: 3792-3810.
［15］	Webster A，Sanders MA，Patel K，et al. Genomic signature of fanconi anaemia DNA repair pathway deficiency in cancer［J］. Nature，2022，612（7940）: 495-502.
［16］	Sheng J，Liu K，Sun D，et al. Association of RDM1 with osteosarcoma progression via cell cycle and MEK/ERK signalling pathway regulation［J］. J Cell Mol Med，2021，25（16）: 8039-8046.
［17］	Xie G，Wu H，Cai W，et al. RDM1 promotes neuroblastoma growth through the RAS-Raf-MEK-ERK pathway［J］. FEBS Open Bio，2019，9（3）: 490-497.
［18］	Li W，Huang Q，Sun D，et al. RDM1 gene overexpression represents a therapeutic target in papillary thyroid carcinoma［J］. Endocr Connect，2017，6（8）: 700-707.
［19］	Goel S，Bergholz JS，Zhao JJ. Targeting CDK4 and CDK6 in cancer［J］. Nat Rev Cancer，2022，22（6）: 356-372.
［20］	Fassl A，Geng Y，Sicinski P. CDK4 and CDK6 kinases: from basic science to cancer therapy［J］. Science，2022，375（6577）: c1495.
［21］	Lloyd MR，Spring LM，Bardia A，et al. Mechanisms of resistance to CDK4/6 blockade in advanced hormone receptor-positive，her2-negative breast cancer and emerging therapeutic opportunities［J］.Clin Cancer Res，2022，28（5）: 821-830.
［22］	Migliaccio I，Bonechi M，Mccartney A，et al. CDK4/6 inhibitors:A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer［J］. Cancer Treat Rev，2021，93: 102136.
［23］	Sager RA，Backe SJ，Ahanin E，et al. Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma［J］. Nat Rev Urol，2022，19（5）: 305-320.
［24］	张艳，吴瑜瑜. 视网膜母细胞瘤基因表达谱芯片的生物信息学分析［J］. 眼科学报，2021，36（5）: 326-332.Zhang Y，Wu YY. Bioinformatics analysis of differentially expressed genes in retinoblastoma［J］. YAN KE XUE BAO，2021，36（5）: 326-332.
［25］	Rubin SM，Sage J，Skotheim JM. Integrating old and new paradigms of G1/S control［J］. Mol Cell，2020，80（2）: 183-192.
［26］	Xu G，Du J，Wang F，et al. RAD52 motif containing protein 1 promotes non small cell lung cancer cell proliferation and survival via cell cycle regulation［J］. Oncol Rep，2018，40（2）: 833-840.
［27］	Qiu C，Li Z，Cao W，et al. Correlation analysis of RDM1 gene with immune infiltration and clinical prognosis of hepatocellular carcinoma［J］. Biosci Rep，2021，41（9）.

变量	单因素		多因素		多因素
变量	HR（95%CI）	P值	HR（95%CI）	P值	HR（95%CI）	P值
年龄（岁）
≤65	参考值		参考值		参考值
＞65	12.28（1.65，91.65）	0.014	12.48（1.58，98.70）	0.017	11.92（1.56，91.17）	0.017
Gleason分级			-		-
1	参考值
2	0.79（0.07，8.71）	0.846
≥3	4.33（0.58，32.51）	0.154
病理T分期					-
T₂	参考值		参考值
T_3a	4.70（1.58，13.95）	0.005	1.38（0.43，4.51）	0.590
T_3b	9.81（3.04，31.60）	＜0.001	0.71（0.16，3.18）	0.659
病理N分期
N₀	参考值		参考值		参考值
N₁	15.00（4.99，45.15）	＜0.001	45.93（9.73，216.85）	＜0.001	40.83（11.64，143.22）	＜0.001
RDM1的IRS评分
≤6	参考值		参考值		参考值
＞6	3.15（1.22，8.13）	0.018	3.34（1.14，9.84）	0.029	2.85（1.08，7.55）	0.035
手术切缘
阴性	参考值		参考值		参考值
阳性	5.73（2.35，13.93）	＜0.001	7.26（2.51，20.99）	＜0.001	6.86（2.54，18.51）	＜0.001

变量	单因素		多因素		多因素
变量	HR（95%CI）	P值	HR（95%CI）	P值	HR（95%CI）	P值
年龄（岁）
≤65	参考值		参考值		参考值
＞65	12.28（1.65，91.65）	0.014	12.48（1.58，98.70）	0.017	11.92（1.56，91.17）	0.017
Gleason分级			-		-
1	参考值
2	0.79（0.07，8.71）	0.846
≥3	4.33（0.58，32.51）	0.154
病理T分期					-
T₂	参考值		参考值
T_3a	4.70（1.58，13.95）	0.005	1.38（0.43，4.51）	0.590
T_3b	9.81（3.04，31.60）	＜0.001	0.71（0.16，3.18）	0.659
病理N分期
N₀	参考值		参考值		参考值
N₁	15.00（4.99，45.15）	＜0.001	45.93（9.73，216.85）	＜0.001	40.83（11.64，143.22）	＜0.001
RDM1的IRS评分
≤6	参考值		参考值		参考值
＞6	3.15（1.22，8.13）	0.018	3.34（1.14，9.84）	0.029	2.85（1.08，7.55）	0.035
手术切缘
阴性	参考值		参考值		参考值
阳性	5.73（2.35，13.93）	＜0.001	7.26（2.51，20.99）	＜0.001	6.86（2.54，18.51）	＜0.001

[1]	Qingshan Luo, Haitao Mei, Jialing Hao, Jinfeng Cai, Runkai Zhou, Yugang Wen. Connexin 43 inhibiting the proliferation of colorectal cancer by regulating the cell cycle [J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(05): 344-349.
[2]	Fu Huang, Qian Wang, Xiangren Jin, Yunchuan Tang. Study on the relationship between the expression of VEGFR2 and miR-27a-5p in gastric cancer tissues and clinicopathological parameters and prognosis [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(05): 558-561.
[3]	Wei Li, Zijian Song, Yancheng Lai, Rui Zhou, Han Wu, Longxin Deng, Rui Chen. The current state and prospects of artificial intelligence applied to prognosis prediction in prostate cancer patients [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(06): 541-546.
[4]	Gongwei Wang, Shuhao Li, Song Wei, Boran Lyu, Cheng Hu. Study on the killing effect of oncolytic virus M1 on different prostate cancer cells [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(06): 626-632.
[5]	Yihui Shi, Pingxin Zhang, Yong Zhu, Delin Yang. Research progress on positive surgical margins after robot assisted radical prostatectomy [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(06): 633-637.
[6]	Siping Hu, Xingyu Xiong, Hang Xu, Lu Yang. The mechanisms of senescence-associated secretory phenotype factors in the occurrence and progression of prostate cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(05): 425-434.
[7]	Yongjun Yang, Yiming Zeng, Xianya He, Qiang Lu, Yuanwei Li. Safety and effectiveness of multi-mode image fusion targeted transperineal biopsy technique under local anaesthesia in patients with ASA grade ≥Ⅲ [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(05): 441-447.
[8]	Xinzhao Li, Tingtao Zhang, Feng Zhu, Jinshan Liu, Dachuang Liu. The value of fibrinogen, D-dimer and alkaline phosphatase in the diagnosis of bone metastasis of prostate cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(05): 459-463.
[9]	Yan Wang, Hongyang Qian, Yinjie Zhu, Baijun Dong, Jiahua Pan, Wei Xue. Preliminary exploration of tumor control effect of robot assisted single port extraperitoneal radical prostatectomy in the treatment of high-risk prostate cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(05): 435-440.
[10]	Jun Zheng, Jieying Wu, Haibo Tan, Anquan Zheng, Tengcheng Li. Construction of EGFR-MEK-TZ combined molecules and it's effects on proliferation and apoptosis of castration-resistant prostate cancer cells [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(05): 503-508.
[11]	Zhao Chen, Keli Zhong, Zhipeng Jiang, Yuxiang Fu, Baohang Fan, Wenfei Wu. Analysis of incidence and risk factors of inguinal hernia after prostate cancer surgery [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2024, 18(04): 396-401.
[12]	Mengmeng Zhao, Jie Huang, Ronghuan Yu, Baoqing Wang. Overexpression of the small GTPase Rab32 inhibits the invasive growth of non-small cell lung cancer cells [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 512-518.
[13]	Yuli Zeng, Farong Lei, Hui Xiao, Deliang Qiu, Jing Xie, Xun Wu. Chloroprocaine inhibits the growth and metastasis of liver cancer Huh-7 cells in vitro by regulating the expression of circRNA-ZKSCAN1 [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2024, 14(04): 220-228.
[14]	Jing Cui, Yifan Bao, Xiaoming Shen, Zenghui Yang, Seng Gao, Chuanqing Bao. Regulation of tumor cell function and sensitivity to 5-FU by circMFSD12 in colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(04): 294-302.
[15]	Ying Jin, Xiaoxia Fu, Meiru Chen, Lu Yuan, Liyao Hao. CD147 promotes cell proliferation and reduces apoptosis in colon cancer cells by regulating the MAPK signaling pathway [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(05): 474-480.

Please choose a citation manager

Content to export